55 patents
Utility
Targeted gene insertion for improved immune cells therapy
16 Jan 24
The invention pertains to the field of adaptive cell immunotherapy.
Brian Busser, Philippe Duchateau, Alexandre Juillerat, Laurent Poirot, Julien Valton
Filed: 19 Oct 17
Utility
Method for generating T-cells compatible for allogenic transplantation
21 Nov 23
The present invention pertains to engineered T-cells, method for their preparation and their use as medicament, particularly for immunotherapy.
Laurent Poirot, David Sourdive, Philippe Duchateau, Jean-Pierre Cabaniols
Filed: 21 Sep 18
Utility
Repeat variable diresidues for targeting nucleotides
10 Oct 23
The present invention relates to polypeptides and more particularly to Transcription Activator-Like Effector derived proteins that allow to efficiently target and/or process nucleic acids.
Philippe Duchateau, Alexandre Juillerat, Claudia Bertonati
Filed: 15 Mar 13
Utility
Sequence specific reagents targeting CCR5 in primary hematopoietic cells
26 Sep 23
The invention pertains to the field of cell therapy and HIV treatments.
Toni Cathomen, Tatjana Cornu, Philippe Duchateau, Claudio Mussolino, Marianna Romito, Agnes Gouble
Filed: 13 Apr 18
Utility
Universal chimeric antigen receptor T cells specific for CD22
4 Jul 23
The present invention relates to new CD22 Chimeric Antigen Receptors (CD22 CAR), an engineered immune cell endowed with said new CD22 CAR and comprising at least inactivated TRAC gene for use in therapy.
Cecile Schiffer-Mannioui, Philippe Duchateau, Anne-Sophie Gautron
Filed: 30 Mar 18
Utility
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
4 Jul 23
Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said immune cells (ex: CD38, CS1 or CD70) by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.
Philippe Duchateau, Laurent Poirot
Filed: 27 Jul 20
Utility
Compact scaffold of Cas9 in the type II CRISPR system
27 Jun 23
The present invention is in the field of CRISPR-Cas system for genome targeting.
Philippe Duchateau, Claudia Bertonati
Filed: 28 May 14
Utility
Canola with high oleic acid
11 Apr 23
Materials and methods for creating canola (e.g., Brassica napus) lines having oil with increased oleic acid content are provided herein.
Wenzheng Zhang, Feng Zhang
Filed: 9 Jul 19
Utility
Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy
14 Mar 23
Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs.
Roman Galetto, Agnès Gouble, Stéphanie Grosse, Cécile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
Filed: 13 May 13
Utility
Large volume ex vivo electroporation method
14 Feb 23
An object of the invention is to provide an electroporation method for treating vesicles with exogenous material for insertion of the exogenous material into the vesicles which includes the steps of: a. retaining a suspension of the vesicles and the exogenous material in a treatment volume in a chamber which includes electrodes, wherein the chamber has a geometric factor (cm−1) defined by the quotient of the electrode gap squared (cm2) divided by the chamber volume (cm3), wherein the geometric factor is less than or equal to 0.1 cm−1, wherein the suspension of the vesicles and the exogenous material is in a medium which is adjusted such that the medium has conductivity in a range spanning 50 microSiemens/cm to 500 microSiemens/cm, wherein the suspension is enclosed in the chamber during treatment, and b. treating the suspension enclosed in the chamber with one or more pulsed electric fields.
Richard E Walters, Alan D King
Filed: 18 Apr 18
Utility
Mutant
14 Feb 23
Materials and methods are provided for making plants (e.g., Nicotiana varieties) that are suitable for producing therapeutic polypeptides suitable for administration to humans and animals, particularly by making TAL effector endonuclease-induced mutations in genes encoding xylosyltransferases and fucosyltransferases.
Luc Mathis, Daniel F. Voytas, Jin Li, Feng Zhang, Thomas Stoddard, Marc-Andre D'Aoust
Filed: 13 Nov 20
Utility
Method for making nicotiana plants with mutations in XylT and FucT alleles using rare-cutting endonucleases
17 Jan 23
Materials and methods are provided for making plants (e.g., Nicotiana varieties) that are suitable for producing therapeutic polypeptides suitable for administration to humans and animals, particularly by making TAL effector endonuclease-induced mutations in genes encoding xylosyltransferases and fucosyltransferases.
Luc Mathis, Daniel F. Voytas, Jin Li, Feng Zhang, Thomas Stoddard, Marc-Andre D'Aoust
Filed: 31 Oct 13
Utility
BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
15 Nov 22
The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a BCMA monoclonal antibody, conferring specific immunity against BCMA positive cells.
Roman Galetto
Filed: 8 May 19
Utility
Alfalfa with reduced lignin composition
25 Oct 22
Materials and methods for creating plants (e.g., alfalfa lines) with reduced lignin content and composition are provided herein, as are plants, plant parts, and plant cells generated by the methods provided herein.
Song Luo, Nicholas J. Baltes
Filed: 25 Apr 18
Utility
Sequential gene editing in primary immune cells
11 Oct 22
The invention pertains to the field of adaptive cell immunotherapy.
Jean-Pierre Cabaniols, Jean-Charles Epinat, Philippe Duchateau
Filed: 30 Jun 17
Utility
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
16 Aug 22
A method of expanding deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex.
Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
Filed: 22 Mar 19
Utility
Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
21 Jun 22
The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy.
Philippe Duchateau, André Choulika, Laurent Poirot
Filed: 18 Feb 20
Utility
Methods for engineering highly active T cell for immunotherapy
26 Apr 22
The present invention relates to methods for developing engineered T-cells for immunotherapy and more specifically to methods for modifying T-cells by inactivating at immune checkpoint genes, preferably at least two selected from different pathways, to increase T-cell immune activity.
Roman Galetto, Agnes Gouble, Stephanie Grosse, Cécile Schiffer-Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
Filed: 13 May 14
Utility
Methods for altering amino acid content in plants through frameshift mutations
26 Apr 22
Materials and methods are provided for making plants with altered levels of amino acids, particularly by making controlled frameshift mutations in genes that are highly expressed in plant leaves or plant seeds.
Nicholas Baltes, Song Luo
Filed: 16 Nov 17
Utility
Methods for engineering allogeneic and highly active t cell for immunotherapy
19 Apr 22
The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive.
Roman Galetto, Agnes Gouble, Stephanie Grosse, Cécile Schiffer-Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
Filed: 13 May 14